FORT LAUDERDALE, Fla., Feb. 11, 2016 -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced the signing of a five year agreement with a Canadian pharmaceutical drug developer. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used for the collection of clinical data during this five year term in numerous global trials spanning Phase I to Phase III clinical studies.
TrialMaster was selected after an exhaustive evaluation that included OmniComm and six other leading EDC solution providers to select the replacement for their legacy EDC application. Specific evaluation emphasis was placed on fast study build time, ease of data extraction in submission ready data format, direct patient data entry and a comprehensive feature set. TrialMaster was found superior in all categories when compared to the other six competing EDC technologies. The depth and breadth of functionality, ease of contracting, and a highly responsive executive management team were significant factors in the selection of TrialMaster EDC.
Trial build time was of particular interest as this clinical development team will be responsible for building their own studies. They found TrialMaster’s rich and versatile design and build toolset easier to learn and easier to work with when compared to the competing technologies and thereby enabling faster study build times. TrialMaster will be deployed within OmniComm’s OmniCloud® for hosting and maintenance of the entire IT infrastructure, ensuring clinical data management technology is always running; data is secure, and product enhancements are rolled out seamlessly.
“We are very pleased that, across a field of highly regarded EDC technologies, OmniComm’s TrialMaster was selected as the best solution by a very knowledgeable and savvy group of clinical professionals,” states Kuno van der Post, SVP of business development, OmniComm. “We are all extremely excited to see this new client showcase our software.”
Supporting Information
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.
Trademarks
OmniComm, OmniCloud, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
OmniComm Systems, Inc. 2101 West Commercial Blvd. Suite 3500 Fort Lauderdale, FL 33309 USA Phone: +1.954.473.1254 Fax: +1.954.473.1256 www.omnicomm.com


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Washington Post Publisher Will Lewis Steps Down After Layoffs 



